B[The Shandong Provincial Government issued the "15th Five-Year Plan for the Development of Traditional Chinese Medicine in Shandong Province"] On November 3, the Shandong Provincial People's Government recently issued the "15th Five-Year Plan for the Development of Traditional Chinese Medicine in Shandong Province", clarifying the goals, tasks and key measures for the development of traditional Chinese medicine in Shandong Province during the "15th Five-Year Plan" period. The "Plan" deploys eight aspects, including continuing to improve the Chinese medicine service system, continuing to improve the health service capabilities of Chinese medicine, accelerating the collaborative integration of Chinese and Western medicine, continuing to strengthen the cultivation of Chinese medicine talents, accelerating the inheritance and innovation of Chinese medicine, accelerating the development of the Chinese medicine industry, continuing to promote the cultural heritage and international exchanges of Chinese medicine, and continuing to deepen the comprehensive reform of Chinese medicine. 27 key tasks, while proposing 33 key projects in 8 columns, including Chinese medicine service system construction projects, Chinese medicine health service capacity improvement projects, Chinese and Western medicine collaborative development projects, Chinese medicine talent cultivation projects, Chinese medicine inheritance and innovation projects, Chinese medicine industry development projects, Chinese medicine cultural inheritance and exchange projects, and Chinese medicine comprehensive reform projects. B[Fujian Province: By 2030, the province’s traditional Chinese medicine planting area will reach 1.2 million acres] November 2, recently, Fujian Province issued “Several Measures to Improve the Quality of Traditional Chinese Medicine in Fujian Province and Promote the High-Quality Development of the Traditional Chinese Medicine Industry.” A total of 18 measures were put forward from six major aspects: promoting the quality and efficiency of the traditional Chinese medicine industry, promoting the optimization and upgrading of the traditional Chinese medicine industry, promoting the innovative and open development of traditional Chinese medicine, strengthening the value assessment and allocation and use of traditional Chinese medicine, strengthening the quality and industry supervision of traditional Chinese medicine, and improving the comprehensive management level and security capabilities. "Several Measures" proposes that by 2030, the province's traditional Chinese medicinal material planting area will reach 1.2 million acres, of which "Fujiuwei" will reach 750,000 acres; 5 Fujian authentic Chinese medicinal material germplasm resource preservation nurseries will be built, and 15 counties will be cultivated to improve the quality and efficiency of Chinese medicinal materials. , 10 planting bases for bulk varieties of authentic medicinal materials; 20 new processing specifications for traditional Chinese medicine pieces and 15 varieties of traditional Chinese medicine formula granules were added, and 10 standardized bases that passed extended GAP inspection of Chinese medicinal materials were built to consolidate the foundation of authentic medicinal materials resources. B[The traditional Chinese medicine sector is active against the trend, and Lingrui Pharmaceutical has hit its daily limit] News on October 30th, the traditional Chinese medicine sector was active against the trend in early trading, with Lingrui Pharmaceutical hitting its daily limit. Previously, Guilin Sanjin had gone out of the two-game board, and Buchang Pharmaceutical, Sunflower Pharmaceutical, Jilin Aodong, and Kangmei Pharmaceutical soared. On the news, Lingrui Pharmaceutical released its third quarter report, which showed that the company’s single-quarter net profit in the third quarter increased by 26.71% year-on-year. B[Hunan: Encourage commercial insurance companies to promote health insurance products with traditional Chinese medicine characteristics such as traditional Chinese medicine for preventing diseases] On October 27, the General Office of the Hunan Provincial People's Government recently issued the "Fifteenth Five-Year Plan for the Development of Traditional Chinese Medicine in Hunan Province" to make arrangements for accelerating the revitalization and development of traditional Chinese medicine in Hunan during the "15th Five-Year Plan" period. The "Plan" proposes to promote the coordinated development of medical care, medical insurance, and medicine. Deepen the reform of public welfare-oriented public Chinese medicine hospitals, and further promote the innovative experience and innovative practices of traditional Chinese medicine in the Sanming medical reform. Accelerate the implementation of the dynamic adjustment mechanism for staffing and improve the operation guarantee mechanism of public traditional Chinese medicine hospitals. Promote the reform of the salary system in public traditional Chinese medicine hospitals and explore forms such as negotiated wages and target annual salaries. In the dynamic adjustment of medical service prices, priority will be given to adjusting traditional Chinese medicine diagnosis and treatment items with proven curative effects and obvious advantages of traditional Chinese medicine. Explore and establish an incentive mechanism for traditional Chinese medicine based on payment based on disease group (DRG) and disease score (DIP). Increase the total budget of compact urban medical groups and county medical communities led by traditional Chinese medicine hospitals, and optimize the surplus retention policy.
Promote per-disease payment for dominant TCM diseases, increase the weight and score of disease groups for dominant TCM diseases, support Shaoyang City in launching a national-level pilot reform of per-disease payment for dominant TCM diseases, and explore and promote experience. Traditional Chinese medicine preparations in pilot medical institutions are distributed and used within the province's medical consortia, specialty alliances, and specialty clusters. Commercial insurance companies are encouraged to promote health insurance products with traditional Chinese medicine characteristics such as traditional Chinese medicine for preventing diseases. B[Hunan Province issues the “15th Five-Year Plan” for the development of traditional Chinese medicine] On October 27, the General Office of the People’s Government of Hunan Province recently issued the “15th Five-Year Plan for the Development of Traditional Chinese Medicine in Hunan Province” to make arrangements for accelerating the revitalization and development of traditional Chinese medicine in Hunan during the “15th Five-Year Plan” period. The "Plan" proposes to anchor the beautiful blueprint of "three highs and four new" and the goal of creating a highland for the development of traditional Chinese medicine in the central region, adhere to integrity and innovation, follow the development laws and characteristics of traditional Chinese medicine, improve the inheritance and innovation development mechanism of traditional Chinese medicine, with the theme of promoting high-quality development, and to meet the people's demand for traditional Chinese medicine health services. The starting point and goal are to improve the ability of traditional Chinese medicine to prevent and treat diseases as the foundation, to support the integration of education, science and technology talents, and to use reform and innovation as the driving force to accelerate the modernization of traditional Chinese medicine and coordinate the coordinated development of causes, industries and culture, so as to provide strong support for decisive progress in the construction of a healthy Hunan during the "15th Five-Year Plan" period.
The "Plan" proposes that by 2030, the traditional Chinese medicine service system covering the entire life cycle of the entire population will be more complete, important results will be achieved in the prevention and treatment of major diseases, the contribution to the health level of residents will be greatly improved, the scientific and technological innovation platform system will be significantly optimized, the industrial development competitiveness will be among the best in the country, the cultural influence of Huxiang traditional Chinese medicine will continue to increase, opening up and cooperation will be deepened, the inheritance and innovation of traditional Chinese medicine will move to a higher level of development, and everyone will have access to traditional Chinese medicine services.
The "Plan" deploys 9 key tasks, including optimizing the layout of traditional Chinese medicine resources, improving the comprehensive service capabilities of traditional Chinese medicine, creating a model for the development of integrated traditional Chinese and Western medicine, building a high-quality traditional Chinese medicine talent introduction and training support system, strengthening the inheritance and technological innovation of traditional Chinese medicine, consolidating the development foundation of the traditional Chinese medicine industry, cultivating modern traditional Chinese medicine industry clusters, promoting the promotion and open development of traditional Chinese medicine culture, and deepening the comprehensive reform of traditional Chinese medicine. A total of 12 columns of key tasks are set. B[The traditional Chinese medicine sector bucked the trend and strengthened, and Kunming Pharmaceutical Group hit its daily limit] On October 19, the traditional Chinese medicine sector bucked the trend and strengthened, Kunming Pharmaceutical Group hit its daily limit, with Darentang, Jichuan Pharmaceutical, Pien Tze Huang, China Resources Jiangzhong, Dong'e Ejiao, and Tongrentang leading the gains. On the news, CITIC Securities Research reported that the market style has become cautious recently, and attention to high-dividend targets of traditional Chinese medicine continues to rise. Against this background, the traditional Chinese medicine sector has become a segmented investment sector with high certainty by virtue of its triple attributes of "low valuation + high dividend + cost improvement". B[Shanghai: Improve the level of diagnosis and treatment with traditional Chinese medicine and expand the types and technologies of diagnosis and treatment with traditional Chinese medicine] On October 13, the Shanghai Municipal Health Commission and the Shanghai Administration of Traditional Chinese Medicine issued the "Notice on Carrying out the Capacity Building of Specialty Specialties (Community) with Traditional Chinese Medicine in Shanghai in 2026." It is mentioned that through this round of capacity building, it will be basically achieved that all community health service centers in the city will have at least one specialty specialty of traditional Chinese medicine. Improve the level of TCM specialty diagnosis and treatment, expand TCM specialty diagnosis and treatment diseases and technologies, optimize the layout of outpatient clinics, and strengthen the configuration of facilities and equipment; rely on the new round of "one district, one brand" brand construction of the four major regional medical alliances of TCM, the "631 Plan" to promote the dominant TCM diseases, and the construction of 55 TCM specialty disease alliances, optimize the diagnosis and treatment plan for key diseases at the grassroots level, strengthen talent training, promote academic inheritance and innovation, and build the community into the main front for TCM services. B[Yunnan: Build an important national medicinal material production and supply base by 2030] On September 30, the Yunnan Provincial People's Government issued the "Yunnan Province's "15th Five-Year Plan" Traditional Chinese Medicine Industry Development Plan". It pointed out that in accordance with the development path of "big industry + big cluster + big variety + big production area + big enterprise", by 2030, the leading role of leading enterprises such as "chain owners" will be fully strengthened, cultivating advantageous and characteristic large varieties with Panax notoginseng as the core, and forming a "one product, one chain" characteristic industrial pattern. The promotion rate of improved varieties of Chinese medicinal materials remains at the forefront in the country, and an important production and supply base of authentic medicinal materials has been established in the country. The influence of brands such as "Top Ten Yunnan Medicines", "Top Ten Health Resources", and "Hometown of Yunnan Medicines" has been significantly enhanced, and Yunnan's right to speak of Chinese medicinal materials has been enhanced. B[Preview: The State Council Information Office holds a press conference on decisive progress in promoting the construction of a healthy China] September 12th, the State Council Information Office will hold a series of press conferences with the theme of "Getting Started with the 15th Five-Year Plan" at 10 a.m. on September 14, 2026 (Monday). Lei Haichao, director of the National Health Commission, Liu Jinfeng, deputy director of the National Health Commission and director of the State Administration of Traditional Chinese Medicine, Shen Hongbing, deputy director of the National Health Commission and director of the National Bureau of Disease Control and Prevention, and Guo Yanhong, spokesperson and deputy director of the National Health Commission, introduced the decisive progress in promoting the construction of a healthy China and answered reporters' questions. B[Four departments regulate the management of anesthesia and psychotropic drugs in medical institutions] On September 9, four departments including the National Health Commission and the State Administration of Traditional Chinese Medicine jointly issued the "Regulations on the Management of Narcotic Drugs and Psychotropic Drugs in Medical Institutions". There are 11 chapters and 73 management regulations in total, focusing on key aspects such as the procurement, storage, issuance, use, recycling, and destruction of anesthetic drugs, and detailing and improving various management requirements. Medicinal narcotic drugs and psychotropic drugs are drugs subject to special management in accordance with laws and regulations in China. They have the dual attributes of being necessary for clinical diagnosis and treatment and prone to dependence and addiction. Their safe and reasonable use is related to the lives and health of the people and social harmony and stability. What are the characteristics of management regulations? First, the scope of application is expanded from medicinal narcotic drugs and Category I psychotropic drugs to all medicinal anesthetic drugs (including medicinal narcotic drugs, Category I psychotropic drugs and Category II psychotropic drugs). The second is to refine the internal management system and training and assessment requirements of medical institutions, and improve the management of key departments such as pharmacies, anesthesiology departments, and operating rooms, as well as working mechanisms for recycling, destruction, and safety emergency response.
Third, relevant provisions on informed consent have been added. Prescribing anesthetic drugs to minors requires the written informed consent of their guardians. The fourth is to actively play the role of informatization in the management of anesthetic drugs in medical institutions. Promote the use of digital intelligence technology to strengthen the full-process management of anesthetic drugs in medical institutions and improve management efficiency. It is reported that the management regulations will be implemented from October 1, 2026. B[Morning session on the fourth day of the 2026 State Talks: Kelun Pharmaceutical, Tasly, etc. enter negotiations] September 8th, at about 8 o'clock today, the morning session on the fourth day of the 2026 National Basic Medical Insurance Drug List Negotiation Bidding and Commercial Insurance Innovative Drug List Price Negotiation officially opened. Reporters observed at the scene that Kelun Pharmaceutical, Luye Pharmaceutical, Chia Tai Tianqing, Shenwei Pharmaceutical, Jiangxi Pharmaceutical Capital Zhangshu, Weikang Pharmaceutical, Tasly, Jilin Aodong, etc. were about 20 Representatives from several companies lined up to enter the venue. This is also the first time since the first day of the state-to-state talks that a large number of traditional Chinese medicine companies and Western medicine companies have begun negotiations to enter the country at the same time. (Reporters Lu Afeng and Yu Miao) B[Six departments: Encourage tea, traditional Chinese medicine, silk and other famous products to enter port exit duty-free shops, departure tax refund shops, city duty-free shops, and high-end supermarkets in accordance with the law and regulations] On September 7, six departments including the Ministry of Industry and Information Technology recently jointly issued the "Opinions on Promoting the High-Quality Development of Historical Classic Industries." Opinions put forward to build a multi-channel overseas platform. Give full play to the role of multilateral cooperation mechanisms such as the high-quality Belt and Road Initiative, the Regional Comprehensive Economic Partnership Agreement, and the Shanghai Cooperation Organization, make good use of open platforms such as the Pilot Free Trade Zone and Hainan Free Trade Port, and strengthen international cooperation in technology, standards, markets and other fields. Organize and implement the "Global Premiere of Classic Brands" to support classic and famous enterprises in launching new products, displaying transactions, and disseminating promotions on key exhibition platforms such as the China International Import Expo, China International Fair for Trade in Services, and China International Consumer Goods Expo. Encourage tea, traditional Chinese medicine, silk and other famous products to enter port exit duty-free shops, departure tax refund shops, city duty-free shops, and high-end supermarkets in accordance with laws and regulations, and support classic famous companies in setting up brand experience centers abroad. B[National Medical Insurance Administration: Will continue to expand the coverage of centralized procurement and guide fair and rational competition in the industry] On September 4, the State Council Information Office held a series of press conferences with the theme of "Starting the 15th Five-Year Plan" to introduce the situation of promoting high-quality development of medical insurance and better serving China-style modernization. According to reports, a total of 12 batches of centralized procurement of drugs have been carried out at the national level, covering 555 types of drugs; 6 batches of centralized procurement of high-value medical consumables have been carried out, covering 142 types of consumables in 9 categories. At the same time, provincial-level centralized procurement has been carried out in various places to continue to facilitate the public's access to high-quality and affordable pharmaceutical products.
In the next step, the medical insurance department will continue to expand the coverage of centralized purchasing. Regularly carry out the centralized procurement of drugs and medical consumables organized by the state, guide local governments to further promote inter-provincial alliance procurement, continue to adhere to the principle of "no centralized procurement of new drugs, centralized procurement of non-new drugs", include more varieties with large clinical use and inflated prices into the scope of procurement, continue to deepen the fields of traditional Chinese medicine, biological drugs, medical consumables and other fields, and effectively reduce the cost burden of the people. At the same time, we adhere to the principles of "stabilizing clinical practice, ensuring quality, resisting involution, and preventing bid-rigging", optimize procurement rules, pay more attention to clinical needs, and guide the industry to compete fairly and rationally through "extremely high prices will lead to elimination, and abnormally low prices without quantity", and resolutely combat bid-rigging in the field of centralized pharmaceutical procurement. In addition, it is required to work together to ensure quality and stable supply. Collaboration with the drug regulatory department will be strengthened to strictly enforce the quality threshold requirements for centralized procurement. We will continue to carry out "full coverage" of inspections of enterprises selected for national centralized procurement and variety sampling, and seriously deal with companies that find problems. Supervise the selected enterprises to fulfill their main responsibilities in ensuring supply and effectively ensure the fulfillment of supply contracts.
Supervision and monitoring will be carried out focusing on the standardization of centralized collection and reporting volume and the implementation of winning results, while optimizing assessments to avoid "one size fits all". Promote direct settlement between medical insurance and pharmaceutical companies, promote centralized procurement of selected drugs into primary medical institutions, private hospitals, and designated retail pharmacies, and expand the scope of public access.
— All loaded —
